Know Cancer

forgot password

A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Cancer

Phase 2
18 Years
Not Enrolling
Endometrial Cancer, Endometrial Neoplasms

Thank you

Trial Information

A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Cancer

Inclusion Criteria:

- The subject has a histologically confirmed diagnosis of EC (endometrioid, serous,
clear cell adenocarcinoma, adenosquamous carcinoma, or mixed histology, any grade)
that is advanced (ie, persistent, locally advanced) or recurrent, and is incurable by
standard therapies and has received one platinum based chemotherapy regimen for EC.

- The subject is at least 18 years old.

- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
or 1.

- The subject has at least one measurable lesion

- Tissue samples from archival or fresh tissue, or a tissue block of the subject's

- The subject has adequate organ and marrow function

- The subject is capable of understanding the informed consent and complying with the
protocol and has signed the informed consent document before any study-specific
screening procedures or evaluations are performed.

- Sexually active subjects of childbearing potential and their partners must agree to
use medically accepted methods of contraception during the course of the study and
for 3 months after discontinuation of study drug.

- Subjects of childbearing potential must have a negative pregnancy test at screening.

Exclusion Criteria:

- The subject has previously been treated with a selective PI3K inhibitor, mTOR
inhibitor, or AKT inhibitor.

- The subject has uterine sarcomas (leiomyosarcoma), mixed Mullerian tumors, squamous
carcinoma of the uterus, and/or adenosarcomas of the uterus.

- Certain restrictions on prior treatments apply

- The subject has not recovered from toxicity due to prior therapy to Grade ≤ 1 or to
pre-therapy baseline (excluding alopecia and peripheral neuropathy).

- The subject has a known primary brain tumor or brain metastasis.

- The subject has any other diagnosis of malignancy or evidence of malignancy (except
non-melanoma skin cancer or in situ carcinoma of the cervix) within 2 years before
screening for this study.

- The subject has a diagnosis of uncontrolled diabetes mellitus or has a fasting plasma
glucose > 160 mg/dL.

- The subject is currently receiving anticoagulation with therapeutic doses of warfarin
(low-dose warfarin ≤ 1 mg/day is permitted).

- The subject has prothrombin time (PT)/international normalized ratio (INR) or partial
thromboplastin time (PTT) test results at screening that are above 1.3 x the
laboratory upper limit of normal.

- The subject has uncontrolled, significant intercurrent illness

- The subject has a baseline corrected QT interval ≥ 470 ms.

- The subject is known to be positive for the human immunodeficiency virus (HIV).
(Note: Baseline HIV screening is not required.)

- The subject is pregnant or breastfeeding.

- The subject has a previously identified allergy or hypersensitivity to components of
the study treatment formulation.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy as defined by overall response rate and progression-free survival (PFS) at 6 months

Outcome Time Frame:

every 8-10 weeks

Safety Issue:


Principal Investigator

Clinical Sciences & Operations

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

January 2010

Completion Date:

March 2013

Related Keywords:

  • Endometrial Cancer
  • Endometrial Neoplasms
  • endometrial cancer
  • endometrial carcinoma
  • carcinoma of the endometrium
  • cancer of the endometrium
  • Neoplasms
  • Endometrial Neoplasms
  • Sarcoma, Endometrial Stromal
  • Adenoma



Investigational Site Number 1526 Newport Beach, California  92663
Investigational Site Number 1239 Augusta, Georgia  30912
Investigational Site Number 1133 Boston, Massachusetts  02115
Investigational Site Number 1325 Columbus, Ohio  43210
Investigational Site Number 1434 Oklahoma City, Oklahoma  73084
Investigational Site Number 1132 Abington, Pennsylvania  19001
Investigational Site Number 1134 Philadelphia, Pennsylvania  19111
Investigational Site Number 1142 Providence, Rhode Island  02905
Investigational Site Number 1527 Dallas, Texas  75230